Advertisement

 

 

Detection of Synchronous Primary Malignancies with 68Ga-Labeled Prostate-Specific Membrane Antigen PET/CT in Patients with Prostate Cancer: Frequency in 764 Patients.

Detection of Synchronous Primary Malignancies with 68Ga-Labeled Prostate-Specific Membrane Antigen PET/CT in Patients with Prostate Cancer: Frequency in 764 Patients.
Author Information (click to view)

Osman MM, Iravani A, Hicks RJ, Hofman MS,


Osman MM, Iravani A, Hicks RJ, Hofman MS, (click to view)

Osman MM, Iravani A, Hicks RJ, Hofman MS,

Advertisement
Share on FacebookTweet about this on TwitterShare on LinkedIn

Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2017 06 0158(12) 1938-1942 doi 10.2967/jnumed.117.190215

Abstract

We evaluated the incidence of synchronous primary malignancies in patients undergoing 68Ga-labeled prostate-specific membrane antigen PET/CT for prostate cancer (PC). Methods: Reports for 764 PC patients were reviewed. Incidental lesions atypical for PC metastases and suggestive of a synchronous primary malignancy were identified. Follow-up was obtained to confirm etiology. Results: Lesions atypical for PC metastases were found in 49 (6.4%) of 764 patients, and a synchronous primary malignancy was confirmed in 5 patients (0.7%; 2 lung, 1 lymphoma, 1 thyroid, and 1 base of tongue). In 8 patients (1.0%), lesions were proven to be atypical metastases from PC. In 24 patients (3.1%), lesions had a benign etiology. Follow-up was not available in 12 patients (1.6%). Conclusion: Synchronous 68Ga-labeled prostate-specific membrane antigen-avid malignancies were rare (0.7%) in PC patients; atypical lesions were more commonly unusual PC metastases (1.0%) or benign (3.1%).

Submit a Comment

Your email address will not be published. Required fields are marked *

15 − ten =

[ HIDE/SHOW ]